Literature DB >> 33047242

Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker.

Angelo Fassio1, Giovanni Adami2, Luca Idolazzi2, Alessandro Giollo2, Ombretta Viapiana2, Emma Bosco2, Riccardo Negrelli3, Elena Sani4, Damiano Sandri4, Alessandro Mantovani4, Giovanni Targher4, Maurizio Rossini2, Davide Gatti2.   

Abstract

We performed a cross-sectional study to investigate the prevalence of Diffuse Idiopathic Skeletal Hyperostosis (DISH) through Dual-Energy X-ray absorptiometry (DXA) Vertebral Fracture Assessment (VFA) in a group of post-menopausal women with Type 2 Diabetes Mellitus (T2DM). We also explored several biomarkers of bone turnover metabolism, including Wnt pathway modulators. DXA-VFA was performed to detect the presence of DISH. Serum samples were collected from all patients at the time of study recruitment. 16 different serum biomarkers were tested between the two subgroups. Given the exploratory nature of the study, we did not adjust for multiplicity. At VFA analysis, among 96 individuals enrolled in the study 20 (20.8%) showed features of DISH. No statistically significant difference was found for BMD values, between the DISH and NO-DISH subgroups. Concerning blood biomarkers, DISH patients showed a significant difference only in the sclerostin serum levels (32 vs 35.5 pmol/L, for the DISH and NO-DISH subgroup, respectively; p = 0.010). After adjustment for confounding factors, sclerostin serum levels remained significantly lower in DISH group (p = 0.002). We demonstrated a non-negligible prevalence of DISH in a population of post-menopausal women affected by T2DM and suggested low serum sclerostin as a possible key feature associated with DISH presence. In addition, we propose DXA-VFA analysis, whose radiation dose is considerably lower than conventional radiography, as a viable diagnostic and prognostic mean to obtain data not only on bone health, but also for the screening for DISH in subjects at risk.

Entities:  

Keywords:  Densitometry; Diffuse idiopathic skeletal hyperostosis; Dkk-1; Osteoporosis; Sclerostin; Type 2 diabetes mellitus; Wnt pathway

Mesh:

Substances:

Year:  2020        PMID: 33047242     DOI: 10.1007/s00223-020-00768-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  25 in total

Review 1.  Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms.

Authors:  Reuven Mader; Jorrit-Jan Verlaan; Dan Buskila
Journal:  Nat Rev Rheumatol       Date:  2013-11-05       Impact factor: 20.543

Review 2.  Diffuse idiopathic skeletal hyperostosis: musculoskeletal manifestations.

Authors:  T A Belanger; D E Rowe
Journal:  J Am Acad Orthop Surg       Date:  2001 Jul-Aug       Impact factor: 3.020

3.  Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes.

Authors:  Luigi Gennari; Daniela Merlotti; Roberto Valenti; Elena Ceccarelli; Martina Ruvio; Maria G Pietrini; Cosimo Capodarca; Maria Beatrice Franci; Maria Stella Campagna; Anna Calabrò; Dorica Cataldo; Konstantinos Stolakis; Francesco Dotta; Ranuccio Nuti
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

4.  Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.

Authors:  A Mantovani; E Sani; A Fassio; A Colecchia; O Viapiana; D Gatti; L Idolazzi; M Rossini; G Salvagno; G Lippi; G Zoppini; C D Byrne; E Bonora; Giovanni Targher
Journal:  Diabetes Metab       Date:  2018-10-10       Impact factor: 6.041

5.  Marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis.

Authors:  G O Littlejohn; H A Smythe
Journal:  J Rheumatol       Date:  1981 Nov-Dec       Impact factor: 4.666

Review 6.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

7.  Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis.

Authors:  L Senolt; H Hulejova; O Krystufkova; S Forejtova; L Andres Cerezo; J Gatterova; K Pavelka; J Vencovsky
Journal:  Ann Rheum Dis       Date:  2011-09-07       Impact factor: 19.103

8.  Insulin is essential for in vitro chondrogenesis of mesenchymal progenitor cells and influences chondrogenesis in a dose-dependent manner.

Authors:  Michael B Mueller; Torsten Blunk; Bernhard Appel; Angelika Maschke; Achim Goepferich; Johannes Zellner; Carsten Englert; Lukas Prantl; Richard Kujat; Michael Nerlich; Peter Angele
Journal:  Int Orthop       Date:  2012-12-11       Impact factor: 3.075

9.  Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography.

Authors:  Daniele Diacinti; Romano Del Fiacco; Daniela Pisani; Federico Todde; Maria Sofia Cattaruzza; Davide Diacinti; Serena Arima; Elisabetta Romagnoli; Jessica Pepe; Cristiana Cipriani; Salvatore Minisola
Journal:  Calcif Tissue Int       Date:  2012-09-11       Impact factor: 4.333

Review 10.  Assessment of vertebral fracture using densitometric morphometry.

Authors:  F Duboeuf; D C Bauer; R D Chapurlat; J M P Dinten; P Delmas
Journal:  J Clin Densitom       Date:  2005       Impact factor: 2.963

View more
  3 in total

Review 1.  Risk factors for the development of degenerative cervical myelopathy: a review of the literature.

Authors:  Guillaume Baucher; Jelena Taskovic; Lucas Troude; Granit Molliqaj; Aria Nouri; Enrico Tessitore
Journal:  Neurosurg Rev       Date:  2021-11-30       Impact factor: 3.042

Review 2.  Diffuse Idiopathic Skeletal Hyperostosis of Cervical Spine with Dysphagia-Molecular and Clinical Aspects.

Authors:  Mikołaj Dąbrowski; Łukasz Kubaszewski
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 3.  The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.

Authors:  Eugenia Bertoldo; Giovanni Adami; Maurizio Rossini; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti; Angelo Fassio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.